Lung cancer is the second most common cancer in the United States and the leading cause of mortality in cancer patients. Biomarkers predicting survival of patients with lung cancer have a profound effect on patient prognosis and treatment. However, predictive biomarkers for survival and their relevance for lung cancer are not been well known yet. The objective of this study was to perform machine learning with data from The Cancer Genome Atlas of patients with lung adenocarcinoma (LUAD) to find survival-specific gene mutations that could be used as survival-predicting biomarkers. To identify survival-specific mutations according to various clinical factors, four feature selection methods (information gain, chi-squared test, minimum redundan...
Abstract Background Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) alw...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Lung cancer is the second most common cancer in the United States and the leading cause of mortality...
We constructed a prognostic-related risk prediction for patients with lung adenocarcinoma by integra...
Abstract Background Lung adenocarcinoma is the most common type of lung cancers. Whole-genome sequen...
After numerous breakthroughs in medicine, microbiology, and pathology in the past century, lung canc...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background: Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) always exhi...
Background. Lung squamous cell carcinoma (LSCC) is a frequently diagnosed cancer worldwide, and it h...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background. After curative surgical resection, about 30-75% lung adenocarcinoma (LUAD) patients suff...
Abstract Background Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) alw...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Lung cancer is the second most common cancer in the United States and the leading cause of mortality...
We constructed a prognostic-related risk prediction for patients with lung adenocarcinoma by integra...
Abstract Background Lung adenocarcinoma is the most common type of lung cancers. Whole-genome sequen...
After numerous breakthroughs in medicine, microbiology, and pathology in the past century, lung canc...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background: Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) always exhi...
Background. Lung squamous cell carcinoma (LSCC) is a frequently diagnosed cancer worldwide, and it h...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...
Background. After curative surgical resection, about 30-75% lung adenocarcinoma (LUAD) patients suff...
Abstract Background Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) alw...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundLung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year overall survival...